This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Orexo AB

Drug Names(s): OX51

Description: OX51 is a reformulation of alfentanil for the treatment and prevention of acute intense pain episodes in opioid-tolerant and opioid-naïve patients treated in the hospital setting. Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/4 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl. It is an OP3 mu-agonist. To date, no one has yet made alfentanil available in an oral tablet formulation.

Deal Structure: Orexo owns all commercial rights to OX51 globally.

OX51 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug